Allison M. Booth

1.1k total citations
8 papers, 23 citations indexed

About

Allison M. Booth is a scholar working on Genetics, Pathology and Forensic Medicine and Biomedical Engineering. According to data from OpenAlex, Allison M. Booth has authored 8 papers receiving a total of 23 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 2 papers in Pathology and Forensic Medicine and 2 papers in Biomedical Engineering. Recurrent topics in Allison M. Booth's work include Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (2 papers) and SAS software applications and methods (2 papers). Allison M. Booth is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (2 papers) and SAS software applications and methods (2 papers). Allison M. Booth collaborates with scholars based in United States and Canada. Allison M. Booth's co-authors include Mark R. Litzow, Richard F. Little, Jennifer R. Brown, Jennifer A. Woyach, John C. Byrd, Carolyn Owen, Richard A. Larson, Richard M. Stone, Sumithra J. Mandrekar and Jeremy S. Abramson and has published in prestigious journals such as Blood, Leukemia and Clinical Lymphoma Myeloma & Leukemia.

In The Last Decade

Allison M. Booth

6 papers receiving 23 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Allison M. Booth United States	4	15	11	9	6	5	8	23
Stephan DiSean Kendall United States	2	19 1.3×	16 1.5×	5 0.6×	6 1.0×	2 0.4×	2	20
Tatiana Chagorova Australia	2	28 1.9×	28 2.5×	5 0.6×	8 1.3×	6 1.2×	3	32
Nisha De Silva Germany	2	23 1.5×	22 2.0×	8 0.9×	10 1.7×	4 0.8×	2	26
M Sopena Spain	3	13 0.9×	5 0.5×	15 1.7×	3 0.5×	3 0.6×	7	23
Janet Schmid United States	4	16 1.1×	11 1.0×	10 1.1×	2 0.3×	4 0.8×	7	25
Maurizio Cantini Italy	3	19 1.3×	5 0.5×	21 2.3×	5 0.8×		9	34
Philip Kuruvilla Canada	4	14 0.9×	4 0.4×	10 1.1×	3 0.5×	6 1.2×	12	29
Zoltán Gasztonyi Hungary	3	10 0.7×	8 0.7×	16 1.8×	8 1.3×		7	22
Kaitlin Kennard United States	3	15 1.0×	15 1.4×	8 0.9×	4 0.7×	1 0.2×	9	25
Giulia Palazzo Italy	5	11 0.7×	12 1.1×	14 1.6×	13 2.2×	2 0.4×	6	36

Countries citing papers authored by Allison M. Booth

Since Specialization

Citations

This map shows the geographic impact of Allison M. Booth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison M. Booth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison M. Booth more than expected).

Fields of papers citing papers by Allison M. Booth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allison M. Booth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison M. Booth. The network helps show where Allison M. Booth may publish in the future.

Co-authorship network of co-authors of Allison M. Booth

This figure shows the co-authorship network connecting the top 25 collaborators of Allison M. Booth. A scholar is included among the top collaborators of Allison M. Booth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allison M. Booth. Allison M. Booth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Ruppert, Amy S., Allison M. Booth, Wei Ding, et al.. (2021). Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 35(10). 2854–2861. 10 indexed citations

Cheung, Matthew C., Nicole Mittmann, Carolyn Owen, et al.. (2021). A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 21(11). 766–774. 3 indexed citations

Woyach, Jennifer A., Amy S. Ruppert, Gabriela Pérez, et al.. (2021). A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL). Blood. 138(Supplement 1). 3728–3728. 1 indexed citations

Cheung, Matthew C., Nicole Mittmann, Carolyn Owen, et al.. (2020). A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia. Blood. 136(Supplement 1). 27–30. 1 indexed citations

Woyach, Jennifer A., Amy S. Ruppert, Gabriela Pérez, et al.. (2019). Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL). Blood. 134(Supplement_1). 1751–1751. 4 indexed citations

Booth, Allison M.. (2012). PROC REPORT Unwrapped: Exploring the Secrets behind One of the Most Popular Procedures in Base SAS ® Software.

Booth, Allison M.. (2011). Beyond the Basics: Advanced REPORT Procedure Tips and Tricks Updated for SAS ® 9.2.

Attar, Eyal C., Kathleen Donohue, Philip C. Amrein, et al.. (2010). Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502. Blood. 116(21). 331–331. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact